Baseline Factors | GEE Linear Regression† | ||
---|---|---|---|
Coefficient | 95% CI | ||
Work | Job type (labor-intensive vs sedentary) | 2.7 | (0.4–4.9)* |
Presenteeism, % | 0.14 | (0.07–0.2)* | |
Clinical | Commencing biologic (yes vs no) | 2.8 | (−1.1 to 6.7)* |
Uveitis (yes vs no) | −1.4 | (−4.0 to 1.1) | |
Psoriasis (yes vs no) | 2.7 | (−2.6 to 8.0) | |
Inflammatory bowel disease (yes vs no) | 1.1 | (−4.3 to 6.4) | |
Dactylitis (yes vs no) | 3.4 | (−6.4 to 13.1) | |
Peripheral joint involvement (yes vs no) | 3.4 | (−0.7 to 7.5)* | |
BASDAI (score 0–10) | 1.2 | (0.7–1.8)* | |
BASFI (score 0–10) | 0.9 | (0.4–1.4)* | |
BASMI (score 0–10) | −0.2 | (−0.9 to 0.4) | |
BAS-G (score 0–10) | 1.1 | (0.6–1.6)* | |
Patient | ASQoL (score 0–18) | 0.5 | (0.3–0.8)* |
EQ-VAS (score 0–100) | −0.1 | (−0.2 to −0.04)* | |
Activity impairment, % | 0.13 | (0.08–0.2)* | |
Spinal pain (score 0–10) | 1.01 | (0.5–1.5)* | |
Chalder Fatigue Scale (score 0–11) | 0.4 | (0.02–0.8)* | |
Sleep disturbance (score 0–20) | 0.4 | (0.2–0.6)* | |
HADS Anxiety (clinical/borderline vs none) | 2.5 | (0.06–4.9)* | |
HADS Depression (clinical/borderline vs none) | 3.2 | (0.07–6.4)* |
↵† Adjusted for age, sex, and deprivation.
↵* Eligible for forward stepwise model (p ≤ 0.2). GEE: generalized estimating equation; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath AS Functional Index; BASMI: Bath AS Metrology Index; BAS-G: Bath AS Global score; ASQoL: AS Quality of Life questionnaire; EQ-VAS: EuroQol visual analog scale; HADS: Hospital Anxiety and Depression Scale.